ATHE

Alterity Therapeutics Limited

NasdaqCMUSDEQUITY DELAYED

4.62

▲ 0.17 (3.82%)

MARKET · —

Price

Open

4.53

Prev close

4.45

Day high

4.68

Day low

4.51

Volume

10.17K

Market cap

—

P/E (TTM)

—

52W range

2.66 – 5.89

Trailing performance

Price return · vs SPY

Returnvs SPY

-2.51% -1.1%

-0.43% -4.2%

+11.72% +8.6%

+41.52% +30.4%

YTD

+51.62% +39.3%

-7.16% -27.2%

+69.82% -4.4%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

4.67

-1.07% from price

SMA 20

4.58

+2.04% from price

SMA 50

4.83

-3.34% from price

SMA 100

4.52

+2.10% from price

SMA 200

3.96

+17.92% from price

EMA 12

4.63

-0.28% from price

EMA 26

4.67

-1.09% from price

EMA 50

4.66

-0.86% from price

RSI (14)

49.9

Neutral

MACD (12,26,9)

-0.04

Hist 0.01

ATR (14)

0.28

5.92% of price

Realised vol 30D

56.6%

Annualised

Bollinger upper

4.87

20, 2σ

Bollinger lower

4.28

20, 2σ

50 / 200 cross

Golden

4.83 vs 3.96

Trend bias

Above 200

+17.92%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.26

More volatile than market

Correlation to SPY

0.25

Largely independent

Realised vol 30D

56.6%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-43.5%

Peak to trough

Max drawdown 5Y

-92.4%

Peak to trough

ATR 14

0.28

5.92% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 4.62

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ATHE · links out to the publisher

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 GlobeNewswire · 10d ago Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference GlobeNewswire · 16d ago Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update GlobeNewswire · 23d ago Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026 GlobeNewswire · 32d ago Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy MT Newswires · 46d ago Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy GlobeNewswire · 46d ago Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? Zacks · 64d ago Top Premarket Decliners MT Newswires · 72d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.